Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Laser Immunotherapy +/- Nivolumab in BCC
NCT04570683Phase 1Unknown
- Sponsor
- Bispebjerg and Frederiksberg Hospital
- Start
- Jan 2020
- Primary completion
- Sep 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of nivolumab in basal cell carcinoma (BCC) (3 arms), sponsored by Bispebjerg and Frederiksberg Hospital. Primary endpoints: Immunological Response at 1 week and Clinical Response at 12 weeks. Status: unknown.
02
Drugs
03
Conditions
basal cell carcinoma (BCC)
Beyond the preview
Go deeper on NCT04570683.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04570683.